Urinary continence 12 months after surgery MCID: 5% absolute difference · men (ages > 18 years) with clinically localized prostate cancer
Posterior reconstruction showed no clear difference in urinary continence 12 months after surgery MCID: 5% absolute… compared with no posterior reconstruction (low certainty).
1 finding from 1 review
Potency 12 months after surgery MCID: 5% absolute difference · men (ages > 18 years) with clinically localized prostate cancer
It is very uncertain whether posterior reconstruction changes potency recovery 12 months after surgery MCID: 5% absolute difference compared with no posterior reconstruction (very low certainty).
1 finding from 1 review
Positive surgical margins MCID: 5% absolute difference · men (ages > 18 years) with clinically localized prostate cancer
Posterior reconstruction showed no clear difference in positive surgical margins MCID: 5% absolute difference compared with no posterior reconstruction (low certainty).
1 finding from 1 review
CRM197‐PCV7in low‐risk infants · infants (predominantly < 6 months of age) and older children (aged 1 to 7 years)
1 finding from 1 review
CRM197‐PCV7in high‐risk infants · infants (predominantly < 6 months of age) and older children (aged 1 to 7 years)
1 finding from 1 review
OMPC‐PCV7in low‐risk infants · infants (predominantly < 6 months of age) and older children (aged 1 to 7 years)
1 finding from 1 review
PHiD‐CV10in low‐risk infants · infants (predominantly < 6 months of age) and older children (aged 1 to 7 years)
1 finding from 1 review
PHiD‐CV11in low‐risk infants · infants (predominantly < 6 months of age) and older children (aged 1 to 7 years)
1 finding from 1 review
Adverse effects · infants (predominantly < 6 months of age) and older children (aged 1 to 7 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
CRM197‐PCV7in low‐risk infants OMPC‐PCV7in low‐risk infants PHiD‐PC10 and PHiD‐PC11 in low‐risk infants CRM197‐PCV7/9 and CRM197‐PCV7 plus TIVin older children · infants (predominantly < 6 months of age) and older children (aged 1 to 7 years)
1 finding from 1 review
Seizure freedom · children (aged 1 to 18 years) with drug‐resistant epilepsy
It is very uncertain whether ketogenic diet (KD) changes seizure freedom (100% reduction in seizure frequency) compared with usual care (very low certainty).
1 finding from 1 review
Cognition and behaviour · adults (aged 16 years and over) with drug‐resistant epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · adults (aged 16 years and over) with drug‐resistant epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment withdrawal · adults (aged 16 years and over) with drug‐resistant epilepsy
It is very uncertain whether ketogenic diet (KD) changes treatment withdrawal compared with usual care (very low certainty).
1 finding from 1 review
Seizure freedom · children (aged 4 months to 16 years) with drug‐resistant epilepsy
1 finding from 1 review
50% or greater reduction in seizure frequency · children (aged 4 months to 16 years) with drug‐resistant epilepsy
1 finding from 1 review
Adverse effects · children (aged 4 months to 16 years) with drug‐resistant epilepsy
1 finding from 1 review
Cognition and behaviour · children (aged 4 months to 16 years) with drug‐resistant epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · children (aged 4 months to 16 years) with drug‐resistant epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Attrition rate · children (aged 4 months to 16 years) with drug‐resistant epilepsy
1 finding from 1 review